Welgene Biotech Co.Ltd.

6661 · TWO · Healthcare / Diagnostics & Research

15.30TWD-0.70 (-4.37%)

Price History

Full chart

Market Stats

Previous Close16.00

Open16.00

Day Range15.30 – 16.55

52-Week Range15.50 – 23.25

Volume9.00K

Market Cap377.53M

P/E (TTM)0.00

Forward P/E0.00

EPS-0.06

Dividend Yield0.00%

Beta0.20

50-Day Avg16.80

200-Day Avg17.86

About

Welgene Biotech Co.,Ltd. engages in the trade of biotechnology-related instruments, reagents, and biotechnology testing services. The company offers research services, including generation, PacBio third generation sequencing; microarray, protein body analysis; nucleic acid extraction/QC, single cell experimental, and bioinformatics analysis services. It also provides reagents, medical consumables, and instruments, as well as software services. Welgene Biotech Co.,Ltd. was founded in 2003 and is based in Taipei City, Taiwan.

Company Details

SectorHealthcare
IndustryDiagnostics & Research
CEODr. Yi Xing Lin
Employees0
HeadquartersNo. 3, Yuanyuan Street, Taipei, Taiwan, 11503, Taiwan
Websitehttps://www.welgene.com.tw

Leadership

Dr. Yi Xing LinGM & Director
Ying-Ren ChenAccounting Supervisor

Financials

Income Statement

Currency: TWD	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	270.18M	277.40M	278.30M	325.78M	384.43M	417.46M	398.10M	312.65M	321.90M	280.55M	322.55M	375.94M
Growth (%)	-	+2.67%	+0.32%	+17.06%	+18.00%	+8.59%	-4.64%	-21.46%	+2.96%	-12.85%	+14.97%	+16.55%
Cost of Revenue	152.84M	144.18M	150.61M	179.51M	206.26M	242.92M	235.80M	179.38M	180.10M	160.83M	186.71M	219.76M
Gross Profit	117.34M	133.22M	127.69M	146.26M	178.17M	174.54M	162.30M	133.27M	141.80M	119.72M	135.84M	156.18M
Gross Margin	43.43%	48.03%	45.88%	44.90%	46.35%	41.81%	40.77%	42.62%	44.05%	42.67%	42.11%	41.54%
Operating Expense	83.47M	108.63M	118.95M	118.72M	139.87M	133.54M	123.61M	121.09M	125.19M	121.43M	136.54M	156.12M
Operating Income	33.87M	24.59M	8.74M	27.55M	38.30M	41.00M	38.69M	12.17M	16.61M	-1.71M	-704.00K	57.00K
Operating Margin	12.54%	8.86%	3.14%	8.46%	9.96%	9.82%	9.72%	3.89%	5.16%	-0.61%	-0.22%	0.02%
EBITDA	38.90M	31.27M	15.64M	35.38M	45.93M	49.03M	57.13M	31.39M	35.66M	25.54M	33.01M	32.54M
EBITDA Margin	14.40%	11.27%	5.62%	10.86%	11.95%	11.74%	14.35%	10.04%	11.08%	9.10%	10.23%	8.65%
Net Income	21.10M	21.29M	4.09M	23.65M	28.34M	30.87M	29.77M	13.70M	9.55M	-2.65M	1.11M	1.33M
Net Income Margin	7.81%	7.68%	1.47%	7.26%	7.37%	7.39%	7.48%	4.38%	2.97%	-0.94%	0.34%	0.35%
R&D	9.96M	11.60M	13.07M	15.94M	15.85M	20.99M	22.00M	21.64M	21.63M	24.14M	25.85M	26.51M
R&D as % of Total Revenue	3.69%	4.18%	4.69%	4.89%	4.12%	5.03%	5.53%	6.92%	6.72%	8.61%	8.01%	7.05%
Interest Expense	3.69M	1.19M	793.00K	720.00K	682.00K	318.00K	654.00K	425.00K	281.00K	2.62M	2.97M	3.41M
Interest Expense % of Total Revenue	1.37%	0.43%	0.28%	0.22%	0.18%	0.08%	0.16%	0.14%	0.09%	0.93%	0.92%	0.91%

Balance Sheet

Currency: TWD	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	222.51M	281.50M	276.03M	312.00M	362.34M	422.25M	360.29M	424.54M	435.71M	548.16M	528.25M	622.19M
Total Liabilities	108.24M	81.80M	72.30M	88.37M	115.79M	171.50M	107.54M	114.47M	131.76M	247.89M	232.50M	336.12M
Total Equity	114.08M	199.49M	203.53M	223.42M	246.32M	250.54M	252.54M	309.86M	303.76M	292.03M	287.91M	281.30M
Cash	97.03M	121.00M	136.21M	138.97M	140.72M	171.29M	160.34M	199.77M	158.59M	188.13M	173.50M	224.33M
Total Debt	49.67M	35.03M	30.29M	37.59M	14.02M	44.30M	29.38M	23.84M	51.19M	154.35M	-	-
Net Debt	-47.36M	-85.97M	-105.92M	-101.39M	-126.70M	-126.99M	-130.96M	-175.92M	-107.40M	-33.78M	-	-

Cash Flow

Currency: TWD	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	15.80M	-9.61M	6.63M	32.26M	48.81M	85.14M	41.77M	11.25M	51.43M	-366.00K	56.08M	35.27M
Financing Cash Flow	-185.67M	49.49M	-5.76M	3.62M	-25.17M	-29.18M	-43.12M	38.52M	-24.61M	23.91M	-	-
Capital Expenditure	14.15M	5.73M	4.10M	8.67M	9.25M	8.64M	5.91M	4.38M	26.86M	27.73M	4.81M	42.04M
Free Cash Flow	1.65M	-15.34M	2.54M	23.59M	39.56M	76.50M	35.86M	6.87M	24.57M	-28.10M	51.27M	-6.77M
Dividends Paid	23.31M	-	-	3.79M	5.97M	26.14M	27.77M	25.68M	11.29M	4.23M	-	-
FCF to OCF	10.45%	159.62%	38.21%	73.13%	81.04%	89.85%	85.84%	61.09%	47.77%	7677.60%	91.43%	-19.20%
Dividend Paid to FCF	1411.87%	-	-	16.06%	15.09%	34.16%	77.43%	373.76%	45.94%	-15.05%	-	-

Earnings

Report Date	Dec 31, 2020	May 12, 2021
EPS Estimate	0.37	0.38
EPS Actual	0.45	-0.25
Surprise	21.62%	-165.79%
Timing	-	Pre-market

Key Statistics & Ratios

Market Cap377.53M

Enterprise Value450.87M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.95

Price / Book1.36

EPS-0.06

Book Value11.72

Revenue (TTM)398.92M

Gross Profit (TTM)166.87M

EBITDA14.31M

Profit Margin-0.41%

Operating Margin-1.19%

Return on Equity-0.49%

Return on Assets-0.26%

Shares Outstanding23.30M

Shares Float5.89M

Beta0.20

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Dividends

20231×

0.18Mar 16, 2023

20221×

0.48Mar 17, 2022

20211×

1.10Jun 9, 2021

20201×

1.34Jun 15, 2020

20191×

1.26Jun 25, 2019

20181×

0.31Aug 17, 2018

Stock Splits

Aug 17, 20181080:1000